David M. Jackman, MD

Publications

• Nishino M, Jackman DM, Hatabu H, Jänne PA, Johnson BE, Van den Abbeele AD.Imaging of lung cancer in the era of molecular medicine.Acad Radiol. 2011 Apr;18(4):424-36.
  21277232
• Nishino M, Guo M, Jackman DM, DiPiro PJ, Yap JT, Ho TK, Hatabu H, Jänne PA, Van den Abbeele AD, Johnson BE.CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.Acad Radiol. 2011 Jan;
  21036632
• Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.Clin Cancer Res. 201
  21030498
• Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD.New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and imp
  20729419
• Sholl LM, Xiao Y, Joshi V, Yeap BY, Cioffredi LA, Jackman DM, Lee C, Jänne PA, Lindeman NI.EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.Am J Clin
  20472851
• Jackman D, Pao W, Riely GJ, Engelman JA, Kris MG, Jänne PA, Lynch T, Johnson BE, Miller VA.Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.J Clin Oncol. 2010 Jan 10;2
  19949011
• Jackman DM.Current options for systemic therapy in mesothelioma.Semin Thorac Cardiovasc Surg. 2009;21(2):154-8. Review.
  19822287
• Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE.Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients:
  19671843
• Souza FF,Jagganathan J,Ramayia N,Johnston C,Jackman D,Abbeele AV,Ros PR.Recurrent malignant peritoneal mesothelioma: radiological manifestations.Abdom Imaging. 2009 Mar 25.
  19319590
• Yonesaka K,Zejnullahu K,Lindeman N,Homes AJ,Jackman DM,Zhao F,Rogers AM,Johnson BE,Janne PA.Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.Clin Cancer Res. 2008 Nov 1;14(21):6963-73.
  18980991
• Costa DB,Nguyen KS,Cho BC,Sequist LV,Jackman DM,Riely GJ,Yeap BY,Halmos B,Kim JH,Janne PA,Huberman MS,Pao W,Tenen DG,Kobayashi S.Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.Clin Cancer Res. 2008 Nov 1;14(2
  18981003
• Cioffredi LA,Janne PA,Jackman DM.Treatment of peritoneal mesothelioma in pediatric patients.Pediatr Blood Cancer. 2009 Jan;52(1):127-9.
  18819151
• Jackman DM,Kindler HL,Yeap BY,Fidias P,Salgia R,Lucca J,Morse LK,Ostler PA,Johnson BE,Janne PA.Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma.Cancer. 2008 Aug 15;113(4):808-14.
  18543326
• Johnson BE, Jackman D, Jänne PA.Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31. Review.
  17671154
• Jackman DM, Jänne PA.Does erlotinib improve symptoms in patients with lung cancer?.Nat Clin Pract Oncol. 2007 Mar;4(3):146-7.
  17262089
• Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age tre
  17228019
• Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE.Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treat
  16983123
• Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK.Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.Cancer. 2006 Sep 1;107(5):975-81.
  16862573
• Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA.Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged s
  16818686
• Jackman DM, Johnson BE.Small-cell lung cancer.Lancet. 2005 Oct 15-21;366(9494):1385-96.
  16226617
• Jackman DM, Chirieac LR, Jänne PA.Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.Semin Respir Crit Care Med. 2005 Jun;26(3):342-52.
  16052436